Responsible for allocating research funding
The Committee for Clinical Therapy Research decides which calls are to be made within the area. They also decide on which applications will be awarded grants. They have three review panels to help them examine and prioritise the applications submitted to the Swedish Research Council, before the Committee takes a decision. The review panels, which are appointed by the Committee, consist of international experts, statisticians and representatives of the Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU).
The research funded by the Committee must
- be clinical and conducted in national collaboration
- be based on the needs of health and medical care
- be expected to lead to benefits for patients and society within a relatively short period of time.
Following up and evaluating research in the area
The Committee follows up, evaluates, and produces strategies for the research area, for example through research overviews. In this work, the Committee is assisted by both national and international experts.
Strategic plan for the The Committee for Clinical Therapy Research 2020–2023
(pdf, 220.4 kB) (in Swedish)
The Swedish Research Council provides funding together with the Swedish Association of Local Authorities and Regions
The Swedish Research Council funds clinical therapy research in collaboration with the Swedish Association of Local Authorities and Regions. The Swedish Association of Local Authorities and Regions contributes half the funds that the Committee awards.
Composition of the Committee
The Committee for Clinical Therapy Research has thirteen members. The Government appoints the chair and six members, three of whom are proposed by the Swedish Research Council (following consultation with Vinnova). The other six members represent the regions and are appointed by the Swedish Association of Local Authorities and Regions, SALAR. Vinnova has a co-opted member of the committee.
The committee meets five times a year
Name | Title | Organisation |
|---|---|---|
Miia Kivipelto, (chair) | Professor, Specialist doctor | Karolinska Institutet, Karolinska University Hospital |
Clas Ahlm | Director of Research and Education, professor, Senior Consultant | Region Västerbotten, Umeå University, Norrlands University Hospital |
Anders Bjartell | Professor, Senior Consultant | Lund University, Skåne University Hospital |
Annette Bruchfeld | Professor, Senior Consultant | Linköping University, Linköping University Hospital |
Anders Christensson | Professor, Chief Medical Officer | Lund University, Skåne University Hospital, Region Skåne |
Lisa Ekselius | Professor, Senior Consultant | Uppsala University, Uppsala University Hospital |
Mia von Euler | Professor, Senior Consultant | Örebro University, Örebro University Hospital |
Clara Hellner | Research and Innovation Director | Region Stockholm |
Magnus Janzon | Center manager, Senior Consultant | Linköping University, Region Östergötland |
Jan Kilhamn | R&D Manager healthcare | Region Västra Götaland |
Bertil Lindahl | Professor, Senior Consultant | Uppsala University, Uppsala University Hospital |
Håkan Olausson | Professor, Senior Consultant | Linkping University, Linköping University Hospital |
Petri Olivius | R&D manager | Region Sörmland |
- In order to obtain a broad international perspective and a secure anchoring in society, the Committee has an advisory group to support the work. It contains representatives from
- The Public Health Agency of Sweden
- Forte, the Swedish Research Council for Health, Working Life and Welfare
- LIF, the Swedish Association of the Pharmaceutical Industry
- Swedish Medical Products Agency
- The Swedish Neurological Association
- The Swedish Rheumatism Association
- Rare Diseases Sweden
- Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)
- National Board of Health and Welfare
- The Swedish National Council on Medical Ethics
- SwedenBIO
- Swedish Medtech
- The Dental and Pharmaceutical Benefits Agency (TLV).
PublISHED ON 25 May 2018
UpDATED ON 04 February 2021